Bristol - Myers Squibb (NYSE: BMY ) will hold a teleconference on Friday, October 31 at 1:30 pm CT/2:30 pm ET to review data presented at the Chicago Multidisciplinary
3M (NYSE: MMM ), Amazon (NASDAQ: AMZN ) Caterpillar (NYSE: CAT ), Procter & Gamble (NYSE: PG ), Bristol Myers (NYSE: BMY ). Other stocks mentioned: Alibaba (NYSE: BABA ), Vodafone (NASDAQ: VOD ), First Solar (NASDAQ: FSLR
s product, Keytruda (pembrolizumab) injection, is currently cleared for the treatment of melanoma. Bristol - Myers Squibb (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) are also players in the space. 1 comment!
Bristol - Myers Squibb (NYSE: BMY ), Pharmacyclics (NASDAQ: PCYC ) and Janssen Research & Development ..... to evaluate the safety, tolerability and preliminary efficacy of BMY 's Opdivo ( nivolumab ) in combination with Imbruvica (ibrutinib
Ingelheim. Then came Xarelto by Johnson & Johnson (NYSE: JNJ ). Finally, Pfizer (NYSE: PFE ) and Bristol - Myers Squibb (NYSE: BMY ) teamed up to release Eliquis. While these drugs are more convenient and have less interactions then Coumadin
By Pharma Doc : Background: The hepatitis C landscape is an extremely competitive area for pharmaceuticals and biotechs. Years ago, the standard of care for HCV genotype 1 patients was Pegasys and Ribavirin for 48 weeks of treatment. Side effects were very bad (nausea and flu-like symptoms), and ...
Bristol - Myers Squibb (NYSE: BMY ) resolves all outstanding U.S. patent litigation related to efavirenz , an active ingredient in Sustiva (efavirenz) and Atripla
(Adds comment from Bristol - Myers and analyst, adds background, updates shares)
Oct 7 (Reuters) - Bristol - Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C.
rapidly evolving hepatitis C treatment landscape," Bristol - Myers Squibb (NYSE: BMY ) decides not to pursue U.S. regulatory approval ..... daclatasvir, a pan-genotypic NS5A complex inhibitor . BMY developed the dual regimen to meet the distinct needs